Cationic polyene phospholipids as DNA carriers for ocular gene therapy

Detalhes bibliográficos
Autor(a) principal: Machado, Susana
Data de Publicação: 2014
Outros Autores: Calado, Sofia, Bitoque, Diogo, Oliveira, Ana Vanessa, Øpstad, Christer L., Zeeshan, Muhammad, Sliwka, Hans-Richard, Partali, Vassilia, Pungente, Michael D., Silva, Gabriela
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.1/9874
Resumo: Recent success in the treatment of congenital blindness demonstrates the potential of ocular gene therapy as a therapeutic approach. The eye is a good target due to its small size, minimal diffusion of therapeutic agent to the systemic circulation, and low immune and inflammatory responses. Currently, most approaches are based on viral vectors, but efforts continue towards the synthesis and evaluation of new nonviral carriers to improve nucleic acid delivery. Our objective is to evaluate the efficiency of novel cationic retinoic and carotenoic glycol phospholipids, designated C20-18, C20-20, and C30-20, to deliver DNA to human retinal pigmented epithelium (RPE) cells. Liposomes were produced by solvent evaporation of ethanolic mixtures of the polyene compounds and coformulated with 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) or cholesterol (Chol). Addition of DNA to the liposomes formed lipoplexes, which were characterized for binding, size, biocompatibility, and transgene efficiency. Lipoplex formulations of suitable size and biocompatibility were assayed for DNA delivery, both qualitatively and quantitatively, using RPE cells and a GFP-encoding plasmid. The retinoic lipoplex formulation with DOPE revealed a transfection efficiency comparable to the known lipid references 3β-[N-(N',N'-dimethylaminoethane)-carbamoyl]-cholesterol (DC-Chol) and 1,2-dioleoyl-sn-glycero-3-ethylphosphocholine (EPC) and GeneJuice. The results demonstrate that cationic polyene phospholipids have potential as DNA carriers for ocular gene therapy.
id RCAP_b55f167811aba42e2bc255e3b1c87224
oai_identifier_str oai:sapientia.ualg.pt:10400.1/9874
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Cationic polyene phospholipids as DNA carriers for ocular gene therapyCationsCell lineCholesterolDNAEpithelium, cornealEyeGene transfer techniquesGenetic therapyGenetic vectorsHumansLiposomesPhosphatidylethanolaminesPhospholipidsPlasmidsPolyenesRetinal pigmentsTransfectionRecent success in the treatment of congenital blindness demonstrates the potential of ocular gene therapy as a therapeutic approach. The eye is a good target due to its small size, minimal diffusion of therapeutic agent to the systemic circulation, and low immune and inflammatory responses. Currently, most approaches are based on viral vectors, but efforts continue towards the synthesis and evaluation of new nonviral carriers to improve nucleic acid delivery. Our objective is to evaluate the efficiency of novel cationic retinoic and carotenoic glycol phospholipids, designated C20-18, C20-20, and C30-20, to deliver DNA to human retinal pigmented epithelium (RPE) cells. Liposomes were produced by solvent evaporation of ethanolic mixtures of the polyene compounds and coformulated with 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) or cholesterol (Chol). Addition of DNA to the liposomes formed lipoplexes, which were characterized for binding, size, biocompatibility, and transgene efficiency. Lipoplex formulations of suitable size and biocompatibility were assayed for DNA delivery, both qualitatively and quantitatively, using RPE cells and a GFP-encoding plasmid. The retinoic lipoplex formulation with DOPE revealed a transfection efficiency comparable to the known lipid references 3β-[N-(N',N'-dimethylaminoethane)-carbamoyl]-cholesterol (DC-Chol) and 1,2-dioleoyl-sn-glycero-3-ethylphosphocholine (EPC) and GeneJuice. The results demonstrate that cationic polyene phospholipids have potential as DNA carriers for ocular gene therapy.Hindawi Publishing CorporationSapientiaMachado, SusanaCalado, SofiaBitoque, DiogoOliveira, Ana VanessaØpstad, Christer L.Zeeshan, MuhammadSliwka, Hans-RichardPartali, VassiliaPungente, Michael D.Silva, Gabriela2017-07-19T14:33:55Z20142014-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.1/9874engAUT: GAS02236;10.1155/2014/703253info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-07-24T10:21:25Zoai:sapientia.ualg.pt:10400.1/9874Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T20:01:42.097464Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Cationic polyene phospholipids as DNA carriers for ocular gene therapy
title Cationic polyene phospholipids as DNA carriers for ocular gene therapy
spellingShingle Cationic polyene phospholipids as DNA carriers for ocular gene therapy
Machado, Susana
Cations
Cell line
Cholesterol
DNA
Epithelium, corneal
Eye
Gene transfer techniques
Genetic therapy
Genetic vectors
Humans
Liposomes
Phosphatidylethanolamines
Phospholipids
Plasmids
Polyenes
Retinal pigments
Transfection
title_short Cationic polyene phospholipids as DNA carriers for ocular gene therapy
title_full Cationic polyene phospholipids as DNA carriers for ocular gene therapy
title_fullStr Cationic polyene phospholipids as DNA carriers for ocular gene therapy
title_full_unstemmed Cationic polyene phospholipids as DNA carriers for ocular gene therapy
title_sort Cationic polyene phospholipids as DNA carriers for ocular gene therapy
author Machado, Susana
author_facet Machado, Susana
Calado, Sofia
Bitoque, Diogo
Oliveira, Ana Vanessa
Øpstad, Christer L.
Zeeshan, Muhammad
Sliwka, Hans-Richard
Partali, Vassilia
Pungente, Michael D.
Silva, Gabriela
author_role author
author2 Calado, Sofia
Bitoque, Diogo
Oliveira, Ana Vanessa
Øpstad, Christer L.
Zeeshan, Muhammad
Sliwka, Hans-Richard
Partali, Vassilia
Pungente, Michael D.
Silva, Gabriela
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Sapientia
dc.contributor.author.fl_str_mv Machado, Susana
Calado, Sofia
Bitoque, Diogo
Oliveira, Ana Vanessa
Øpstad, Christer L.
Zeeshan, Muhammad
Sliwka, Hans-Richard
Partali, Vassilia
Pungente, Michael D.
Silva, Gabriela
dc.subject.por.fl_str_mv Cations
Cell line
Cholesterol
DNA
Epithelium, corneal
Eye
Gene transfer techniques
Genetic therapy
Genetic vectors
Humans
Liposomes
Phosphatidylethanolamines
Phospholipids
Plasmids
Polyenes
Retinal pigments
Transfection
topic Cations
Cell line
Cholesterol
DNA
Epithelium, corneal
Eye
Gene transfer techniques
Genetic therapy
Genetic vectors
Humans
Liposomes
Phosphatidylethanolamines
Phospholipids
Plasmids
Polyenes
Retinal pigments
Transfection
description Recent success in the treatment of congenital blindness demonstrates the potential of ocular gene therapy as a therapeutic approach. The eye is a good target due to its small size, minimal diffusion of therapeutic agent to the systemic circulation, and low immune and inflammatory responses. Currently, most approaches are based on viral vectors, but efforts continue towards the synthesis and evaluation of new nonviral carriers to improve nucleic acid delivery. Our objective is to evaluate the efficiency of novel cationic retinoic and carotenoic glycol phospholipids, designated C20-18, C20-20, and C30-20, to deliver DNA to human retinal pigmented epithelium (RPE) cells. Liposomes were produced by solvent evaporation of ethanolic mixtures of the polyene compounds and coformulated with 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) or cholesterol (Chol). Addition of DNA to the liposomes formed lipoplexes, which were characterized for binding, size, biocompatibility, and transgene efficiency. Lipoplex formulations of suitable size and biocompatibility were assayed for DNA delivery, both qualitatively and quantitatively, using RPE cells and a GFP-encoding plasmid. The retinoic lipoplex formulation with DOPE revealed a transfection efficiency comparable to the known lipid references 3β-[N-(N',N'-dimethylaminoethane)-carbamoyl]-cholesterol (DC-Chol) and 1,2-dioleoyl-sn-glycero-3-ethylphosphocholine (EPC) and GeneJuice. The results demonstrate that cationic polyene phospholipids have potential as DNA carriers for ocular gene therapy.
publishDate 2014
dc.date.none.fl_str_mv 2014
2014-01-01T00:00:00Z
2017-07-19T14:33:55Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.1/9874
url http://hdl.handle.net/10400.1/9874
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv AUT: GAS02236;
10.1155/2014/703253
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Hindawi Publishing Corporation
publisher.none.fl_str_mv Hindawi Publishing Corporation
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799133247286804480